SynthesisMedicine2026
Renoprotective effects and safety of sodium-glucose cotransporter 2 inhibitors in diabetic chronic kidney disease: A systematic review and meta-analysis.
Synthesis in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChronic kidney disease (CKD) is a major global health burden characterized by progressive loss of renal function and high cardiovascular morbidity and mortality. Sodium-glucose cotransporter 2 (SGLT2) inhibitors, initially developed as glucose-lowering agents, have demonstrated pleiotropic metabolic and cardiorenal benefits. However, previous evidence syntheses have not fully clarified the magnitude of metabolic, hemodynamic, renal surrogate, and safety effects specifically in patients with diabetic CKD.
methodsA systematic search of PubMed, Embase, Web of Science, and the Cochrane Library was conducted up to December 2025. Randomized controlled trials (RCTs) evaluating SGLT2 inhibitors in patients with diabetic CKD were included. Outcomes were prespecified and grouped as primary renal surrogate marker outcomes (eGFR and UACR), secondary metabolic and hemodynamic outcomes (glycated hemoglobin, body weight, and blood pressure indicators), and safety outcomes (urinary tract infection and volume depletion-related adverse events). Meta-analyses were performed using RevMan 5.3 and R version 4.4.2 software.
resultsA total of 17 randomized controlled trials involving 29,192 participants were included. For secondary metabolic and hemodynamic outcomes, SGLT2 inhibitors significantly reduced glycated hemoglobin levels (MD = -0.40%, 95% CI: -0.44 to -0.36), body weight (MD = -1.36 kg, 95% CI: -1.55 to -1.18), and systolic blood pressure (MD = -2.98 mm Hg, 95% CI: -3.44 to -2.52). For primary renal surrogate marker outcomes, no statistically significant differences were observed in eGFR (MD = 0.25 mL/min/1.73 m2, 95% CI: -0.08 to 0.57) or UACR (MD = -31.55 mg/g, 95% CI: -137.21 to 74.12). Regarding safety outcomes, SGLT2 inhibitors did not significantly increase the risk of urinary tract infections (RR = 1.20, 95% CI: 0.94 to 1.54) but were associated with a significantly higher risk of volume depletion-related adverse events (RR = 1.36, 95% CI: 1.16-1.59).
conclusionIn patients with diabetic CKD, SGLT2 inhibitors significantly improve glycemic control, reduce body weight, and lower systolic blood pressure, while showing neutral short- to medium-term effects on eGFR and albuminuria. These neutral surrogate-marker findings should be interpreted alongside large outcome trials showing long-term cardiorenal protection. Although SGLT2 inhibitors increase the risk of volume depletion-related adverse events, their overall safety profile remains acceptable with appropriate clinical monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.